Jefferies Group’s Agilon Health AGL Stock Holding History

Jefferies Group’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-600	Closed	-$405K	–	1506
2021 Q4	$405K	Hold	600	–	–	﹤0.01%	1233
2021 Q3	$393K	Buy	+600	New	+$513K	﹤0.01%	1306

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Jefferies Group's AGL Position: Q1 2022 in Review

Jefferies Group sold out of Agilon Health (AGL) in Q1 2022, closing a stake of 566 shares — an estimated $382K sold.

Jefferies Group first reported a position in AGL in Q2 2021 and held it in 3 quarters. The position peaked at $382K in Q4 2021. 121 funds tracked by Wall St. Rank hold AGL as of Q1 2022.

Jefferies Group reported no remaining Agilon Health position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 566 Agilon Health shares in Q1 2022, an estimated $382K.
Jefferies Group first reported a position in Agilon Health in Q2 2021 and held it in 3 quarters.
Jefferies Group's Agilon Health position peaked at $382K in Q4 2021.
121 funds tracked by Wall St. Rank held Agilon Health as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.